
LXEO Stock Forecast & Price Target
LXEO Analyst Ratings
Bulls say
Lexeo Therapeutics is poised for success with its promising gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases, including the lead candidates LX2006 and LX2020. The company has a strong pipeline with multiple presentations at ASGCT highlighting progress, and a Phase I/II trial demonstrating significant improvement in FA patients. With a diversified portfolio and potential global reach, Lexeo has the potential for high peak sales, making it a solid investment opportunity with a valuation of $17 per share. However, investors must consider the risks associated with the company's focus on AAV-based GT therapies, potential competition, and the need for further financing prior to achieving profitability.
Bears say
Lexeo Therapeutics is a clinical-stage genetic medicine company with a portfolio of gene therapy candidates targeting genetic causes of cardiovascular diseases. While their therapies show promise to address high unmet medical needs, the company faces strong competition, including from companies with advanced clinical programs and multiple GT products for similar indications. Despite some positive clinical data and evidence of sustained or deepening improvements in cardiac and neurological measures, there are still challenges in interpreting the data and demonstrating consistency and differentiation from natural history. Additionally, the company may face regulatory hurdles and may need to raise additional capital before achieving profitability.
This aggregate rating is based on analysts' research of Lexeo Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LXEO Analyst Forecast & Price Prediction
Start investing in LXEO
Order type
Buy in
Order amount
Est. shares
0 shares